TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.

Scott T Tagawa,Daniel P. Petrylak,Petros Grivas,Neeraj Agarwal,Cora N. Sternberg,Chris Hernandez,Peggy Siemon-Hryczyk,Trishna Goswami,Yohann Loriot

TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.

2019

Scott T Tagawa
Daniel P. Petrylak
Petros Grivas
Neeraj Agarwal
Cora N. Sternberg
Chris Hernandez
Peggy Siemon-Hryczyk
Trishna Goswami
Yohann Loriot

TPS495Background: Patients (pts) with unresectable locally advanced or metastatic urothelial cancer (mUC) who progress after platinum-based chemotherapy and checkpoint inhibitor (CPI) therapy and p...

Keywords:

Cancer
PD-L1
Pathology
Oncology
Sacituzumab govitecan
Chemotherapy
Internal medicine
Medicine
immune checkpoint inhibitors
urothelial cancer
Ineligibility
open label study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations